Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease

Next Previous
Trial Profile

A Phase Ib/IIa Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses, Regimens and Combinations of Tau Targeted Vaccines in Subjects With Early Alzheimer's Disease

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 35.030 (Primary) ; JACI 35.054 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors AC Immune

Most Recent Events

  • 25 Mar 2025 According to an AC Immune media release, data from this study will be presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2025) taking place in Vienna, Austria, on April 1-5, 2025
  • 16 Jul 2024 Time frame for primary measure 'Adverse Events' changed from screening up to week 74 to baseline up to week 74. New primary measure 'Anti-enriched paired helical filaments (ePHF) IgG titers in blood' added newly.
  • 14 Mar 2024 According to an AC Immune media release, clinical expenses (CHF 2.0 million), the company had a net decrease in clinical expenditures largely due the completion of the Phase 1b/2a and the advancement into Phase 2b for our ACI-35.030 active immunotherapy. Company increased expenditures for the continued clinical development of our Phase 1b/2 ABATE study for ACI-24.060.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top